Sequential personalized neoantigen vaccination following first‐line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma
International Journal of Cancer · 01.08.2026 · 159 (3) · 709-718
DOI: 10.1002/ijc.70445 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 16.03.2026. Verfasst von Zhixiong Cai und 16 weiteren Autor:innen. Beteiligte Einrichtung: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical Unive…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cancer Vaccines, Antigens, Neoplasm. Die Arbeit nennt 12 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific Foundation of Fujian Province, Fujian Provincial Health Technology Project.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) has limited therapeutic options in the advanced stages; although first‐line combinations of transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) and/or programmed cell death protein 1 (PD‐1) inhibitors show promise, their efficacy is constrained by inadequate tumor‐specific T‐cell infiltration. To address this limitation, we conducted an investigator‐initiated, single‐center clinical trial (ChiCTR2300067818) evaluating the safety, feasibility, and preliminary efficacy of sequential personalized neoantigen vaccination following TACE plus TKI/PD‐1‐based therapy in patients with advanced HCC. Whole‐exome and transcriptome sequencing identified patient‐specific neoantigens, which were synthesized as long peptides and formulated with dual adjuvants for subcutaneous administration. Among 10 initially enrolled patients, 4 received personalized vaccination after comprehensive screening, with 2 patients (N03 and N04) completing the full 8‐injection vaccination regimen. Sequential neoantigen vaccination demonstrated excellent safety profiles, with only mild injection‐site reactions observed. Both patients achieved partial response following vaccination. Interferon‐gamma Enzyme‐Linked ImmunoSpot assays confirmed robust neoantigen‐specific responses against multiple peptide pools in both patients. Dynamic monitoring revealed that serum alpha‐fetoprotein and Des‐gamma‐carboxy prothrombin levels correlated with clinical responses, declining significantly during vaccination. These findings demonstrate that sequential personalized neoantigen vaccination following first‐line TACE‐based therapy is safe, feasible, and capable of inducing potent tumor‐specific immune responses, supporting further investigation in larger clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Interventional Department, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- State Key Laboratory of Drug Research, Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China.
ORCID-Profile: Wuhua Guo, Xinhui Huang, Xiaolong Liu
Förderung
- National Natural Science Foundation of China
- Scientific Foundation of Fujian Province
- Fujian Provincial Health Technology Project
- Fuzhou City Health and Technology Project
Zitieren
APA
Cai, Z., Qiu, L., Li, L., Li, Z., Zhang, K., Lin, Y., Zhou, Y., Dong, X., Chen, G., Xie, R., Lin, J., Zeng, Y., Yu, H., Fang, Z., Guo, W., Huang, X., & Liu, X. (2026). Sequential personalized neoantigen vaccination following first‐line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma. International Journal of Cancer, 159(3), 709-718. https://doi.org/10.1002/ijc.70445
Vancouver
Cai Z, Qiu L, Li L, Li Z, Zhang K, Lin Y, et al. Sequential personalized neoantigen vaccination following first‐line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma. International Journal of Cancer. 2026;159(3):709-718. doi:10.1002/ijc.70445
BibTeX
@article{Cai2026,
author = {Cai, Zhixiong and Qiu, Liman and Li, Ling and Li, Zhenli and Zhang, Kailiang and Lin, Yan and Zhou, Yang and Dong, Xiuqing and Chen, Geng and Xie, Rong and Lin, Jianhui and Zeng, Yongyi and Yu, Haijun and Fang, Zhuting and Guo, Wuhua and Huang, Xinhui and Liu, Xiaolong},
title = {Sequential personalized neoantigen vaccination following first‐line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {3},
pages = {709--718},
doi = {10.1002/ijc.70445}
}
EUVIMED